Chemotherapy-Induced Endothelial Dysfunction: a Bibliometric Analysis of Research Trends from 1994 to 2024

Aiganym Amanova 1, Saule K. Balmagambetova 2 * , Zhenisgul Tlegenova 1, Kulparshan Kubenova 3, Gulnara Kurmanalina 1, Bekbolat Zholdin 1
More Detail
1 Department of Internal Diseases-2, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
2 Department of Oncology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
3 Clinical Laboratory at University Medical Center, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 22, Issue 5, pp. 24-33. https://doi.org/10.23950/jcmk/17021
OPEN ACCESS 327 Views 169 Downloads
Download Full Text (PDF)
Author Contributions: Conceptualization, A.A. and B.Z.; methodology, S.B., and Z.T.; software, A.A.; validation, Z.T.., G.K. and K.K.; formal analysis, S.B.; investigation, A.A.; resources, G.K. and B.Z; data curation, G.K. and K.K.; writing—original draft preparation, A.A.; writing—review and editing, S.B.; visualization, A.A.; supervision, Z.T.; project administration, B.Z.; funding acquisition, K.K. All authors have read and agreed to the final version of the manuscript.

ABSTRACT

Chemotherapy-induced endothelial damage is a complex issue characterized by cardiovascular toxicity and cellular injury.
This study aims to analyze primary research areas related to chemotherapy-induced endothelial dysfunction, focusing on countries, institutions, journals, authors, and keywords.  
Methods. The research employs a descriptive bibliometric design to collect and analyze data from 3,430 publications indexed in the Web of Science and Scopus databases, spanning the years 1994-2024. The bibliometric analysis includes English-language research articles and review papers examining endothelial dysfunction in chemotherapy patients. Data analysis was conducted using RStudio and the Bibliometrix R package, with VOSviewer utilized for visualization.
Results. The annual publication trend reveals fluctuations, peaking in 2005 while showing sustained interest in recent years. The United States leads in publication volume with 1,328 articles, closely followed by China and Japan. High levels of international collaboration were noted, particularly between the United States and European countries. Key contributing institutions include Harvard Medical School in the USA and the National Cancer Institute, while prominent authors such as Wang and Kim make significant contributions to the field. "Cancer Research" is recognized as one of the most influential journals, highlighting the interdisciplinary relevance of this field.
Conclusions. This bibliometric analysis highlights the evolving key research trends related to angiogenesis, VEGF inhibitors, and the need to increase international cooperation. Given the recent introduction of new classes and groups of chemotherapeutic drugs into practice and the growing body of knowledge in this area, a renewed surge of interest in this topic can be anticipated.
Keywords: endothelial dysfunction, vascular toxicity, cancer research, chemotherapy, bibliometric analysis, publication trends

CITATION

Amanova A, Balmagambetova SK, Tlegenova Z, Kubenova K, Kurmanalina G, Zholdin B. Chemotherapy-Induced Endothelial Dysfunction: a Bibliometric Analysis of Research Trends from 1994 to 2024. J CLIN MED KAZ. 2025;22(5):24-33. https://doi.org/10.23950/jcmk/17021

REFERENCES

  • World Health Organization. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). (Accessed 14 Feb, 2025).
  • Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43 (41): 4229-4361. https://doi.org/10.1093/eurheartj/ehac244.
  • Blaes A, Nohria A, Armenian S, Bergom C, Thavendiranathan P, Barac A, Sanchez-Petitto G, Desai S, Zullig LL, Morgans AK, Herrmann J. Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations. JACC CardioOncol. 2025; 7 (1):1-19. https://doi.org/10.1016/j.jaccao.2024.06.006.
  • Grakova EV, Shilov SN, Kopeva KV, Berezikova EN, Popova AA, Neupokoeva MN, Ratushnyak ET, Teplyakov AT. Anthracycline-Induced Cardiotoxicity: The Role of Endothelial Dysfunction. Cardiology. 2021; 146 (3): 315-323. https://doi.org/10.1159/000512771.
  • Szczepaniak P, Siedlinski M, Hodorowicz-Zaniewska D, Nosalski R, Mikolajczyk TP, Dobosz AM, Dikalova A, Dikalov S, Streb J, Gara K, Basta P, Krolczyk J, Sulicka-Grodzicka J, Jozefczuk E, Dziewulska A, Saju B, Laksa I, Chen W, Dormer J, Tomaszewski M, Maffia P, Czesnikiewicz-Guzik M, Crea F, Dobrzyn A, Moslehi J, Grodzicki T, Harrison DG, Guzik TJ. Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism. J Clin Invest. 2022; 132 (13):e149117. https://doi.org/10.1172/JCI149117.
  • Fredslund SO, Buus NH, Højgaard Skjold C, Laugesen E, Jensen AB, Laursen BE. Changes in vascular function during breast cancer treatment. Br J Clin Pharmacol. 2021; 87 (11): 4230-4240. https://doi.org/10.1111/bcp.14837.
  • Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001; 19(4): 1195-206. https://doi.org/10.1200/JCO.2001.19.4.1195.
  • Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol. 1986; 4 (9):1405-17. https://doi.org/10.1200/JCO.1986.4.9.1405.
  • Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology. 1985; 42 (5): 296-300. https://doi.org/10.1159/000226049.
  • Hansen SW, Olsen N, Rossing N, Rørth M. Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol. 1990; 1 (4): 289-92. https://doi.org/10.1093/oxfordjournals.annonc.a057750.
  • Moseley PL, Hemken C, Hunninghake GW. Augmentation of fibroblast proliferation by bleomycin. J Clin Invest. 1986; 78 (5): 1150-4. https://doi.org/10.1172/JCI112695.
  • Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, de Vries EG, Sleijfer DT. Long-term chemotherapy-related cardiovascular morbidity. Cancer Treat Rev. 2000; 26 (6): 429-47. https://doi.org/10.1053/ctrv.2000.0175.
  • Kohn S, Fradis M, Ben-David J, Zidan J, Robinson E. Nephrotoxicity of combined treatment with cisplatin and gentamicin in the guinea pig: glomerular injury findings. Ultrastruct Pathol. 2002; 26 (6): 371-82. https://doi.org/10.1080/01913120290104683.
  • Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos MA, Papadimitriou C. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012; 38 (5): 473-83. https://doi.org/10.1016/j.ctrv.2011.09.002.
  • Mikacenic C, Hahn WO, Price BL, Harju-Baker S, Katz R, Kain KC, Himmelfarb J, Liles WC, Wurfel MM. Biomarkers of Endothelial Activation Are Associated with Poor Outcome in Critical Illness. PLoS One. 2015; 10 (10):e0141251. https://doi.org/10.1371/journal.pone.0141251.
  • Doroszko A, Niedzielska E, Jakubowski M, Porwolik J, Turek-Jakubowska A, Szahidewicz-Krupska E, Sieczkowski B, Dobrowolski P, Radziwon A, Skomro R, Derkacz A, Mazur G, Chybicka A, Szuba A. Endothelial Function in Children with Acute Lymphoblastic Leukemia (ALL) May Reflect the Clinical Outcome. Biomed Res Int. 2018; 2018:7918091. https://doi.org/10.1155/2018/7918091.
  • Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol. 2001; 280 (4): C719-41. https://doi.org/10.1152/ajpcell.2001.280.4.C719.
  • Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer. 2003; 104 (1): 121-9. https://doi.org/10.1002/ijc.10907.
  • Shi Y, Ji S, Xu Y, Ji J, Yang X, Ye B, Lou J, Tao T. Global trends in research on endothelial cells and sepsis between 2002 and 2022: A systematic bibliometric analysis. Heliyon. 2023; 10 (1): e23599. https://doi.org/10.1016/j.heliyon.2023.e23599.
  • Chen JY, Ye ZX, Wang XF, Chang J, Yang MW, Zhong HH, Hong FF, Yang SL. Nitric oxide bioavailability dysfunction involves in atherosclerosis. Biomed Pharmacother. 2018; 97: 423-428. https://doi.org/10.1016/j.biopha.2017.10.122.
  • Anderson TJ. Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk. Can J Cardiol. 2006; 22 (Suppl B): 72B-80B. https://doi.org/10.1016/s0828-282x(06)70990-4.
  • Osterlund P, Kinos S, Pfeiffer P, Salminen T, Kwakman JJM, Frödin JE, Shah CH, Sorbye H, Ristamäki R, Halonen P, Soveri LM, Heervä E, Ålgars A, Bärlund M, Hagman H, McDermott R, O'Reilly M, Röckert R, Liposits G, Kallio R, Flygare P, Teske AJ, van Werkhoven E, Punt CJA, Glimelius B. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study. ESMO Open. 2022; 7 (3): 100427. https://doi.org/10.1016/j.esmoop.2022.100427.
  • Galán-Arriola C, Villena-Gutiérrez R, Higuero-Verdejo MI, Díaz-Rengifo IA, Pizarro G, López GJ, Molina-Iracheta A, Pérez-Martínez C, García RD, González-Calle D, Lobo M, Sánchez PL, Oliver E, Córdoba R, Fuster V, Sánchez-González J, Ibanez B. Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovasc Res. 2021; 117 (4): 1132-1143. https://doi.org/10.1093/cvr/cvaa181.
  • Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96 (12): 1788-95. https://doi.org/10.1038/sj.bjc.6603813.
  • Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017; (11): 2388-2397. https://doi.org/10.1038/leu.2017.245.
  • Wallin JA. Bibliometric methods: pitfalls and possibilities. Basic Clin Pharmacol Toxicol. 2005; 97 (5): 261-75. https://doi/10.1111/j.1742-7843.2005.pto_139.x